Phase III trial shows lanadelumab reduces HAE attacks in children
Takeda has announced late-breaking Phase III trial data showing that Takhzyro® (lanadelumab) reduces hereditary angioedema (HAE) attacks by roughly 95 percent in children aged two to
List view / Grid view
Takeda has announced late-breaking Phase III trial data showing that Takhzyro® (lanadelumab) reduces hereditary angioedema (HAE) attacks by roughly 95 percent in children aged two to
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
Results of a clinical trial has led to the FDA approval of a monoclonal antibody drug called lanadelumab, to treat hereditary angioedema attacks...